Vepoloxamer

Drug Profile

Vepoloxamer

Alternative Names: ANX-188; CRL-5861; FLOCOR; MST-188; Poloxamer 188 NF; Purified 188; Purified poloxamer 188

Latest Information Update: 02 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytRx Corporation
  • Developer Mast Therapeutics; Savara Pharmaceuticals
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Cell membrane structure modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Veno-occlusive disorders
  • Phase II Myocardial infarction
  • Preclinical Stroke
  • No development reported Acute lung injury; Cancer; CNS disorders; Muscular dystrophies; Peripheral nervous system diseases
  • Discontinued Chronic heart failure; Peripheral arterial occlusive disorders; Sickle cell anaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Apr 2017 Mast Therapeutics has merged with Savara Pharmaceuticals and will operate under the name Savara Pharmaceuticals
  • 08 Nov 2016 Discontinued - Phase-II for Chronic heart failure in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top